Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

BrokerNews newsroom brief · 2h ago · 1 min read · via cnbc.com

The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.

The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA. This story matters for Finance & Markets readers tracking broker. Reported by cnbc.com. Read the full original at the source link below.

Originally reported by cnbc.com. BrokerNews curates and briefs the finance & markets stories that matter. Our editorial policy →

Across the eCorp newsroom network

LendingNews — Nvidia unveils new AI model and expands Japan’s physical AI ecosystem
OptionNews — The Lehman Brothers of the AI bubble is coming, says this critic warning of a fallout for tech and the entire market
BondNews — Wall Street's profit boom has Europe ripping up its banking rulebook
CurrencyNews — UnitedHealth’s stock rallies on improved outlook for the year

Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

More from BrokerNews

Across the eCorp newsroom network